[News Article] Cytiva and Bayer partner to develop allogenic cell therapy platform
Cytiva and Bayer
partner to develop allogenic cell therapy platform
Cytiva and Bayer have partnered to develop what they
claim is the first modular end-to-end manufacturing platform for allogenic cell
therapies.
By Millie Nelson, BioPress International - The multi-year development
deal, of which no financial details have been disclosed, is already underway
and aims to deliver production solutions to meet industry demands.
Cytiva and Bayer say that this partnership will help to establish industry
standards for manufacturing through their shared vision of a modular allogenic
cell therapy manufacturing platform. The end goal is to accelerate speed to
market and reduce costs of production infrastructure through a jointly created
modular design of processes and equipment.
Both parties will provide resources, staff, and facilities to accelerate
the development program. Cytiva will supply its equipment, manufacturing
knowledge, and technology roadmap to design the platforms, and when complete,
the firm will work to make them commercially available.
“At Bayer we anticipate leveraging our existing Biotech team for this
program and we will add staff as needed,” a spokesperson for the firm told BioProcess
Insider.
Furthermore, Bayer’s development product portfolio will be used as
candidates to support proof of concept testing of the technologies and the
firm’s allogeneic cell therapy manufacturing technology will also be used.
“Collaborations are key to advancing and accelerating the development of
novel therapeutics and ultimately helping improve patients’ lives,” Catarina
Flyborg, vice president, Cell and Gene Therapy, Cytiva said. “Cytiva has a strong history as a leader in therapeutic manufacturing
technologies and our collaboration with Bayer and their deep expertise in cell
therapy development will enable us to create a new generation of manufacturing
solutions specifically designed to meet the developing needs of allogeneic cell
therapy.”
According to Cytiva and Bayer, the decision to partner showcases their
commitment to accelerating the development of cell and gene therapies and their
accessibility.
“By combining forces, we believe that we can significantly reduce the time
needed (historically taken 7-10 years) to design and align with industry on as
a manufacturing consensus platform. Our goal is that we will be testing our
first prototypes within the next one to two years with more mature solutions
available within two years thereafter,” the spokesperson for Bayer said.
Source: https://bioprocessintl.com/bioprocess-insider/deal-making/cytiva-and-bayer-partner-to-develop-allogenic-cell-therapy-platform/
2022.07.08
>
>
